Resistance development:
HBV-polymerase inhibitors
HBV-polymerase inhibitors
Resistance (% patients)
Year of treatment
Mutation
1
2
3
4
5
3TC
23
46
55
71
80
A181T/V; M204V/I
ADV
HBeAg pos
HBeAg neg
3TC resist.
0
0
0–32
—
3
0–58
—
11
—
20
18
—
—
29
—
A181T/V; N236T
ETV
naive
3TC resist
0.2
6
0.5
15
1.2
36
1.2
46
1.2
51
I169T; L180M;T184S/A/I/L/G/C/M;
S202C/G/I;
M204V/M250I/V
FTC
HBeAg pos
HBeAg neg
20
5
19–37
—
—
—
A181T/V; M204V/I
LdT
HBeAg pos
HBeAg neg
5
2
25
10.8
A181T/V; M204I
Modified from S. Locarnini,
invited lecture, IAS 2007. Abstract MOBS103